FDA Approves Keytruda QLEX™: A Fast, Convenient Injectable Cancer Immunotherapy for Most Solid Tumors

On September 19, 2025, the FDA approved Keytruda QLEX™, also known as pembrolizumab and berahyaluronidase alfa-pmph, for subcutaneous injection in adults across most solid tumor indications for which standard Keytruda is already used. Unlike the intravenous (IV) form, which takes about 30 minutes to infuse, the new version can be administered by a healthcare professional in as little as one minute every three weeks—or two minutes every six weeks—expanding access to lifesaving immunotherapy both in clinics and local healthcare settings.

Key Findings and Developments

• Keytruda QLEX™ retains the same active ingredient (pembrolizumab) and is approved for all adult and pediatric solid tumor indications as the IV Keytruda, which includes 18 cancer types such as melanoma, lung, breast, and colon cancers.

• Clinical trials demonstrated that the injectable formulation provides at least equivalent blood levels of the drug (AUC geometric mean ratio of 1.14, 96% CI: 1.06–1.22), ensuring comparable clinical effectiveness.

• The new subcutaneous injection could be especially advantageous for patients who have difficult-to-access veins or who wish to avoid long clinic visits. It offers flexibility with two dosing schedules: 395 mg every three weeks or 790 mg every six weeks.

• Merck projects rapid adoption: up to 40% of U.S. Keytruda patients may switch to the more convenient injection by 2027, when broader biosimilar competition is expected to arrive.

Expert Perspectives

Dr. J. Thaddeus Beck, an oncologist and clinical trials director, remarked, “We now have a new option with a broad set of indications that has demonstrated comparability with intravenous (IV) pembrolizumab but in a subcutaneous injection that can be administered in one minute every three weeks or two minutes every six weeks…providing more choices of health care settings in which patients can receive their therapy”.

Independent cancer specialists who were not involved in the research also note the potential for improving patient quality of life. Dr. Lisa Austin, a medical oncologist at a major U.S. cancer center, commented, “Speed and convenience are more than simple luxuries. For those facing advanced cancers, reducing clinic time offers real emotional and logistical relief, particularly for people with mobility challenges or those living far from major hospitals”.

Context and Background

Keytruda is the world’s top-selling drug, generating nearly $30 billion globally last year and prescribed to more than 2.9 million people worldwide. Approved in 2014, its original IV form is a mainstay in cancer care, notably in immunotherapy regimens where the medication empowers the body’s own immune system to seek out and destroy cancer cells.

The launch of Keytruda QLEX comes as Merck anticipates greater competition from lower-cost biosimilars after Keytruda’s IV patent expires in 2028. With this move, Merck aims to meet patient needs for more flexible, streamlined treatment—and to maintain its market leadership.

Implications for Public Health

• The injectable formulation allows for broader access to care, potentially enabling treatment at community clinics and smaller centers, not just major cancer hospitals.

• It reduces time in the chair from 30 minutes to as little as one, helping patients whose veins are hard to access, or who do not require a central venous port.

• For the healthcare system, faster administration may boost clinic efficiency and capacity without compromising cancer care quality.

• From a broader perspective, this move may also delay the use of less expensive biosimilar forms, raising discussion about patient benefit versus healthcare costs.

Limitations and Alternate Views

• No direct clinical outcome data comparing the subcutaneous and intravenous forms in terms of survival or disease progression have been released as of approval. Equivalence has been established based on blood drug levels and short-term safety and efficacy.

• Some advocacy groups express concern that this “evergreening” strategy—introducing a new formulation ahead of patent expiry—may keep drug costs higher for both patients and insurers.

• As of now, the price of Keytruda QLEX has not been disclosed; affordability and insurance coverage will be critical to its future impact.

Practical Takeaways

• For people prescribed Keytruda for eligible cancers, healthcare providers will soon be able to offer a new injection that may take only one or two minutes per dose.

• Patients can discuss with their care team whether this new method might suit their personal and logistical needs.

• The medication’s safety and effectiveness remain comparable to the established IV formulation, but regular medical oversight and consultation continue to be essential.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.